Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35665782

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Jul 7
First author
Modi S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Aug;19(8):493. doi: 10.1038/s41571-022-00663-9.
    note
    Source null
    related pmid
    35778612
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 Jul 7;387(1):75-76. doi: 10.1056/NEJMe2206661.
    note
    Source null
    related pmid
    35793210
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 Sep 22;387(12):1143-1144. doi: 10.1056/NEJMc2210368.
    note
    Source null
    related pmid
    36130004
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 Sep 22;387(12):1144. doi: 10.1056/NEJMc2210368.
    note
    Source null
    related pmid
    36130005
    relationship
    Comment in
  5. citation
    J Nucl Med. 2023 Jul;64(7):1164-1165. doi: 10.2967/jnumed.123.265434.
    note
    Source null
    related pmid
    37230529
    relationship
    Comment in

Authors and identifiers

  1. name
    Modi S
    type
    Author
  2. name
    Jacot W
    type
    Author
  3. name
    Yamashita T
    type
    Author
  4. name
    Sohn J
    type
    Author
  5. name
    Vidal M
    type
    Author
  6. name
    Tokunaga E
    type
    Author
  7. name
    Tsurutani J
    type
    Author
  8. name
    Ueno NT
    type
    Author
  9. name
    Prat A
    type
    Author
  10. name
    Chae YS
    type
    Author
  11. name
    Lee KS
    type
    Author
  12. name
    Niikura N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Modi S
    type
    Author
  2. name
    Jacot W
    type
    Author
  3. name
    Yamashita T
    type
    Author
  4. name
    Sohn J
    type
    Author
  5. name
    Vidal M
    type
    Author
  6. name
    Tokunaga E
    type
    Author
  7. name
    Tsurutani J
    type
    Author
  8. name
    Ueno NT
    type
    Author
  9. name
    Prat A
    type
    Author
  10. name
    Chae YS
    type
    Author
  11. name
    Lee KS
    type
    Author
  12. name
    Niikura N
    type
    Author
bibliography ids
  1. nci-bib-ade762e134665fb9c1623f8d
book metadata
content sha256
1e58091b01104640b3fa4090996a9e656e6c52cdae1efd16c7695065f41cb048
document type
citation
dois
  1. 10.1056/NEJMoa2203690
electronic publication date
display
2022 Jun 5
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35665782
immutable id
pubmed:35665782@1e58091b01104640b3fa4090996a9e656e6c52cdae1efd16c7695065f41cb048
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
1
name
The New England journal of medicine
nlm unique id
0255562
pages
9-20
volume
387
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Aug;19(8):493. doi: 10.1038/s41571-022-00663-9.
    note
    Source null
    related pmid
    35778612
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 Jul 7;387(1):75-76. doi: 10.1056/NEJMe2206661.
    note
    Source null
    related pmid
    35793210
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 Sep 22;387(12):1143-1144. doi: 10.1056/NEJMc2210368.
    note
    Source null
    related pmid
    36130004
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 Sep 22;387(12):1144. doi: 10.1056/NEJMc2210368.
    note
    Source null
    related pmid
    36130005
    relationship
    Comment in
  5. citation
    J Nucl Med. 2023 Jul;64(7):1164-1165. doi: 10.2967/jnumed.123.265434.
    note
    Source null
    related pmid
    37230529
    relationship
    Comment in
outcomes validated
false
pmid
35665782
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
bc495ba61dfdc5e475888858a58668c8c98894a360e6494f06203bbd96bedd32
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Jul 7
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35665782/
title
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Preserved source evidence · Not medical advice